Schedule 13G ownership disclosure
Keros Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 492327101
Event date: 2025-11-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ExodusPoint Capital Management, LP
Shares: 1,907,899 · Class: 6.3%
- ExodusPoint Capital Partners GP, LLC
Shares: 1,907,899 · Class: 6.3%
- Michael Gelband
Shares: 1,907,899 · Class: 6.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000905148-25-004126
- Form type
- SCHEDULE 13G
- Filer
- ExodusPoint Capital Management, LP
- CIK
- CIK 1736225
- Filed
- Nov 18, 2025
- Reporting period
- Nov 10, 2025
- Description
- Schedule 13G beneficial ownership